Annapolis, MD – According to filings with the U.S. Securities and Exchange Commission, Alphyn Biologics is raising $1,500,000.00 in new funding. Sources indicate as part of senior management Chairman and CEO, Neal Koller played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Alphyn Biologics

Alphyn is a life science company developing proprietary drug therapy for treating serious skin diseases.  The initial target indication are skin infections caused by deadly drug-resistant MRSA bacteria based on our proprietary  Multi-Target Therapeutic (MTT) plant-derived technology platform. Alphyn is using its AB-101 platform to apply its therapy-leading Multi-targeted Therapeutics strategy for its first two novel patent-pending topical treatments: one for bacterial skin infections, specifically MRSA Drug Resistant Infections, and 1 for Basal Cell Skin Cancer.

To learn more about Alphyn Biologics, visit http://alphynbiologics.com/

Contact:
Neal Koller, Chairman and CEO
443-994-0101

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved